One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Radiation Dose De-Escalation in HPV-Positive Oropharynx Cancer: When Will It Be an Acceptable Standard of Care?
Anupama Chundury, MD1 and Sung Kim, MD1
doi : 10.1200/JCO.21.00017
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 947-949.
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments
Ian F. Tannock , MD, PhD1; Mark J. Ratain , MD2; Daniel A. Goldstein , MD3; Allen S. Lichter , MD4; Gary L. Rosner , ScD5; and Leonard B. Saltz , MD6
doi : 10.1200/JCO.20.02768
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 950-955.
Reduced-Dose Radiation Therapy for HPV-Associated Oropharyngeal Carcinoma (NRG Oncology HN002)
Sue S. Yom , MD1; Pedro Torres-Saavedra, PhD2; Jimmy J. Caudell, MD3; John N. Waldron, MD4; Maura L. Gillison, MD5; Ping Xia, PhD6; Minh T. Truong, MD7; Christina Kong, MD8; Richard Jordan, PhD1; Rathan M. Subramaniam, MD9; Min Yao , MD10; Christine H. Chung , MD3; Jessica L. Geiger, MD6; Jason W. Chan , MD1; Brian O'Sullivan , MD4; Dukagjin M. Blakaj, MD11; Loren K. Mell , MD12; Wade L. Thorstad, MD13; Christopher U. Jones , MD14; Robyn N. Banerjee, MD15; Christopher Lominska, MD16; and Quynh-Thu Le , MD17
doi : 10.1200/JCO.20.03128
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 956-965.
Reducing radiation treatment dose could improve the quality of life (QOL) of patients with good-risk human papillomavirus–associated oropharyngeal squamous cell carcinoma (OPSCC). Whether reduced-dose radiation produces disease control and QOL equivalent to standard chemoradiation is not proven.
Phase III Trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers: Results From JAVELIN Gastric 100
Markus Moehler , MD, PhD1; Mikhail Dvorkin, MD, PhD2; Narikazu Boku , MD, PhD3; Mustafa ?zgüro?lu , MD4; Min-Hee Ryu, MD, PhD5; Alina S. Muntean, MD, PhD6; Sara Lonardi , MD7; Marina Nechaeva, MD8; Arinilda C. Bragagnoli, MD9; Hasan S. Co?kun, MD10; Antonio Cubillo Gracian, MD, PhD11,12; Toshimi Takano , MD13; Rachel Wong , MBBS14; Howard Safran, MD15; Gina M. Vaccaro, MD16; Zev A. Wainberg , MD17; Matthew R. Silver, PhD18; Huiling Xiong, PhD18; Janet Hong, PharmD18; Julien Taieb , MD, PhD19; and Yung-Jue Bang , MD, PhD20
doi : 10.1200/JCO.20.00892
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 966-977.
The role of maintenance therapy for gastric (GC) or gastroesophageal junction cancer (GEJC) is unclear. We investigated avelumab (anti–programmed death ligand-1 [PD-L1]) maintenance after first-line induction chemotherapy for GC/GEJC.
Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial
Arjen van der Veen, MD1; Hylke J. F. Brenkman, MD, PhD1; Maarten F. J. Seesing, MD, PhD1; Leonie Haverkamp, MD, PhD1; Misha D. P. Luyer, MD, PhD2; Grard A. P. Nieuwenhuijzen, MD, PhD2; Jan H. M. B. Stoot, MD, PhD3; Juul J. W. Tegels, MD, PhD3; Bas P. L. Wijnhoven, MD, PhD4; Sjoerd M. Lagarde, MD, PhD4; Wobbe O. de Steur, MD5; Henk H. Hartgrink, MD, PhD5; Ewout A. Kouwenhoven, MD, PhD6; Eelco B. Wassenaar, MD, PhD7; Werner A. Draaisma, MD, PhD8; Suzanne S. Gisbertz, MD, PhD9; Donald L. van der Peet, MD, PhD10; Anne M. May, PhD11; Jelle P. Ruurda, MD, PhD1; Richard van Hillegersberg, MD, PhD1; and LOGICA Study Group
doi : 10.1200/JCO.20.01540
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 978-989.
The oncological efficacy and safety of laparoscopic gastrectomy are under debate for the Western population with predominantly advanced gastric cancer undergoing multimodality treatment.
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1)
Manish A. Shah , MD1; Gyorgy Bodoky, MD, PhD2; Alexander Starodub, MD3; David Cunningham , OBE, MD4; Desmond Yip , MB BS5; Zev A. Wainberg , MD6; Johanna Bendell, MD7; Dung Thai, MD, PhD8; Joyce He, PhD8; Pankaj Bhargava , MD8; and Jaffer A. Ajani , MD9
doi : 10.1200/JCO.20.02755
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 990-1000.
Andecaliximab (ADX) is a monoclonal antibody that inhibits matrix metalloproteinase 9, an extracellular enzyme involved in matrix remodeling, tumor growth, and metastases. A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin
Alan F. List, MD1; Zhuoxin Sun, PhD2; Amit Verma, MD3; John M. Bennett, MD4; Rami S. Komrokji, MD1; Kathy McGraw, PhD1; Jaroslaw Maciejewski, MD, PhD5; Jessica K. Altman, MD6; Puneet S. Cheema, MD7; David F. Claxton, MD8; Selina M. Luger, MD9; Ryan J. Mattison, MD10; Timothy R. Wassenaar, MD11; Andrew S. Artz, MD12; Charles A. Schiffer, MD13; Mark R. Litzow, MD14; and Martin S. Tallman, MD15
doi : 10.1200/JCO.20.01691
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1001-1009.
Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can restore and improve hemoglobin response to epoetin (EPO) alfa in patients with lower-risk, non-del(5q) MDS who have anemia that is refractory to or have low probability of benefit from treatment with recombinant erythropoietin.
Incidence and Predictors of Mental Health Outcomes Among Survivors of Adolescent and Young Adult Cancer: A Population-Based Study Using the IMPACT Cohort
Riddhita De, MSc1; Rinku Sutradhar, PhD2,3; Paul Kurdyak, PhD3,4,5; Suriya Aktar, MSc2; Jason D. Pole, PhD2,3,6,7; Nancy Baxter, PhD5,8,9; Paul C. Nathan, MD1,2,5,10; and Sumit Gupta, PhD1,2,5,10
doi : 10.1200/JCO.20.02019
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1010-1019.
Risk and predictors of long-term mental health outcomes in survivors of adolescent and young adult (AYA) cancers are poorly characterized. Mental health is consequently neglected in long-term follow-up.
Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma
David F. McDermott , MD1; Jae-Lyun Lee , MD2; Georg A. Bjarnason , MD, FRCPC3; James M. G. Larkin , PhD, FRCP4; Rustem A. Gafanov , MD, PhD5; Mark D. Kochenderfer, MD6; Niels Viggo Jensen, MD7; Frede Donskov , MD, DMSc8; Jahangeer Malik, MD9; Alexandr Poprach, PhD10; Scott S. Tykodi, MD, PhD11; Teresa Alonso-Gordoa, MD12; Daniel C. Cho, MD13; Poul F. Geertsen, MD, PhD14; Miguel Angel Climent Duran, MD, PhD15; Christopher DiSimone, MD, PhD16; Rachel Kloss Silverman, PhD17; Rodolfo F. Perini, MD17; Charles Schloss , MD17; and Michael B. Atkins, MD18
doi : 10.1200/JCO.20.02363
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1020-1028.
Pembrolizumab, a programmed death 1 inhibitor, demonstrated promising single-agent activity in untreated patients with various cancer types. The phase II KEYNOTE-427 study evaluated efficacy and safety of single-agent pembrolizumab in treatment-naive patients with advanced clear cell renal cell carcinoma (ccRCC; cohort A) and advanced non-ccRCC (cohort B). Results of cohort A are reported.
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
David F. McDermott , MD1; Jae-Lyun Lee , MD2; Marek Ziobro , MD, PhD3; Cristina Suarez, MD, PhD4; Przemyslaw Langiewicz, MD5; Vsevolod Borisovich Matveev , MD, PhD6; Pawel Wiechno, MD, PhD7; Rustem Airatovich Gafanov , MD, PhD8; Piotr Tomczak, MD, PhD9; Frederic Pouliot, MD, PhD, FRCSC10; Frede Donskov , MD, DMSc11; Boris Yakovlevich Alekseev, MD12; Sang Joon Shin, MD, PhD13; Georg A. Bjarnason , MD, FRCPC14; Daniel Castellano, MD15; Rachel Kloss Silverman, PhD16; Rodolfo F. Perini, MD16; Charles Schloss , MD16; and Michael B. Atkins, MD17
doi : 10.1200/JCO.20.02365
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1029-1039.
Programmed death 1 (PD-1) pathway inhibitors have not been prospectively evaluated in patients with non–clear cell renal cell carcinoma (nccRCC). The phase II KEYNOTE-427 study (cohort B) was conducted to assess the efficacy and safety of single-agent pembrolizumab, a PD-1 inhibitor, in advanced nccRCC.
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
Nasser H. Hanna, MD1; Andrew G. Robinson , MD2; Sarah Temin , MSPH3; Sherman Baker Jr, MD4; Julie R. Brahmer, MD5; Peter M. Ellis, MD, PhD6; Laurie E. Gaspar, MD, MBA7,8; Rami Y. Haddad, MD9; Paul J. Hesketh , MD10; Dharamvir Jain, MD11; Ishmael Jaiyesimi, MD12; David H. Johnson, MD, MACP13; Natasha B. Leighl , MD14; Pamela R. Moffitt15; Tanyanika Phillips, MD16; Gregory J. Riely , MD, PhD17; Rafael Rosell , MD18; Joan H. Schiller , MD19; Bryan J. Schneider, MD20; Navneet Singh , MD, DM21; David R. Spigel , MD22; Joan Tashbar23; and Gregory Masters , MD24
doi : 10.1200/JCO.20.03570
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1040-1091.
To provide evidence-based recommendations updating the 2017 ASCO guideline on systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC) with driver alterations. A guideline update for systemic therapy for patients with stage IV NSCLC without driver alterations was published separately.
Remarkable Healthy Cohort of Patients With Cancer
Karlijn de Joode, MD, Anne-Marie C. Dingemans, MD, PhD and Astrid A. M. van der Veldt, MD, PhD
doi : 10.1200/JCO.20.03283
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1092-1093.
Reply to K. de Joode et al
Gagandeep Brar, MD, Laura C. Pinheiro, PhD, MPH, Manuel Hidalgo, MD, PhD, and Manish A. Shah, MD
doi : 10.1200/JCO.20.03530
Journal of Clinical Oncology 39, no. 9 (March 20, 2021) 1093-1094.
